Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 20, 2014
Document Information [Line Items]
Entity Registrant Name	AmpliPhi Biosciences Corp
Entity Central Index Key	0000921114
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	APHB
Entity Common Stock, Shares Outstanding		187,159,093
Document Type	10-Q/A
Amendment Flag	true
Document Period End Date	Sep. 30, 2014
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014
Amendment Description	The Company’s previously issued September 30, 2014 financial statements have been amended to: reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at September 30, 2014 of $1,660,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000. recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase of in revenue of $103,000 and an increase of in G&A expense of $73,000 in the third quarter of 2014 and a reduction in revenues of $2,000 and a reduction in G&A expense of $88,000 for the nine months ended September 30, 2014. reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $195,000 as of September 30, 2014. adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants under a Monte Carlo valuation model. The change in assumptions resulted in a increase of $6,410,000 for the compound derivative liability and a decrease in the liability for 2013 warrants of $1,109,000. The gain on derivative liabilities was increased by $2,104,000 and $1,260,000 for the third quarter and the nine months ended September 30, 2014, respectively. As a result of these corrections, the Company’s net income attributable to common stockholders for the third quarter of 2014, as amended, increased $1,496,000 to $20,884,000. Net income per share attributable to common stockholders rose by $0.01 per share to $0.11 per share. Net income attributable to common stockholders for the nine months ended September 30, 2014, as amended, increased by $56,000 to $22,818,000. Net income per share attributable to common stockholders was unchanged for the period. The Company’s net loss attributable to common stockholders for the third quarter of 2013, as amended, increased by ($5,139,000) to ($49,039,000). The net loss per share attributable to common stockholders increased by ($0.05) per share to $(0.49) per share. The net loss attributable to common stockholders for the nine months ended September 30, 2013, as amended, increased by ($7,098,000) to ($65,430,000). The net loss per share attributable to common stockholders increased by ($0.08) per share to $(0.76) per share for the period.